No Data
Chordia Therapeutics: Extraordinary Report
Chordia Therapeutics: Confirmation letter
Chordia Therapeutics: Financial Report - 7th Term (2023/09/01 - 2024/08/31)
Chordia Therapeutics Focuses on Innovative Drug Development
Stocks that moved the previous day part 1 Rain Wind Sun, Dai Do Group HD, SHIFT etc.
Stock name <Code> 27th closing price ⇒ Compared to the previous day Advantest <6857> 8506 -328 fell below the 25-day line the previous day and closed out sell orders| Monster Lab <5255> 117 -2KDDI Technology joined in the development of AI solutions for retail store promotion but temporary popularity did not continue| Pixel CZ <2743> 79 +16Concluded a purchase agreement for GPU servers equipped with NVIDIA's H100. GNI <2160> 2953 +145 consolidated
Emerging Markets Stock Digest: Daiomu significantly declines, Chordia rebounds significantly after 3 days.
<2160> GNI 2953 +145 sharply extended. They are disclosing questions and answers from investors. On the 14th, the consolidated subsidiary Cullgen entered into a contract for a reverse merger with Pulmatrix, listed on the Nasdaq, and expected to record other income of approximately 14.7 billion 64 million yen (with a stock valuation gain of approximately 10.7 billion 68 million yen), but following an increase in Pulmatrix's stock price, in this disclosure, it was mentioned that "the stock valuation gain we record is also significantly increased".
No Data
No Data